News

Life Sciences

Molecular Templates Signs Cancer Therapy Development Deal with Takeda Worth up to $663 Million

Molecular Templates Signs Cancer Therapy Development Deal with Takeda Worth up to $663 Million

Equities Research | Equities.com |

Targeting CD38, a key biomarker in multiple myeloma and other cancers (Image: Molecular Templates).


Galera Therapeutics Secures $150 Million Series C for Oral Mucositis in Cancer Patients

Equities Research | Equities.com |

Equity + royalty financing for Phase 3 trial of lead product candidate in Q4 2018 (Image: Galera Therapeutics).


Braeburn Shows Positive Top-Line Phase 3 Data in Chronic Low Back Pain

Equities Research | Equities.com |

Weekly and monthly buprenorphine for patients previously on long-term daily opioid therapy (Image: Braeburn)


Y-mAbs Therapeutics' $80 Million IPO Expected This Week for Pediatric Cancer

Equities Research | Equities.com |

Two Phase 2 Breakthrough Therapy candidates licensed from Memorial Sloan Kettering (Image: Y-mAbs Therapeutics).


Boehringer Ingelheim Acquires ViraTherapeutics and its Oncolytic Virus Program for $245 Million

Equities Research | Equities.com |

Third major acquisition of an oncolytic virus company by Big Pharma this year (Image: UCLA Jonsson Comprehensive Cancer Center).


Principia Biopharma's $75 Million IPO Expected This Week for Small Molecule Drug Discovery

Equities Research | Equities.com |

Novel drug discovery platform with programs in immunology, central nervous system disorders and oncology (Image: Principia Biopharma).


Merck KGaA and Pfizer Show that Phase 3 Combination Therapy Delays Progression of Kidney Cancer

Equities Research | Equities.com |

Bavencio (avelumab) + Inlyta (axitinib) show statistically significant improvement in progression-free survival vs Sutent (sunitinib) (Image: prIME Oncology).


Kodiak Sciences Files $100 Million IPO for Chronic Retinal Diseases

Equities Research | Equities.com |

Lead candidate targeting wet age-related macular degeneration and diabetic retinopathy.


Twentyeight-Seven Therapeutics Launches with $65 Million for Cancer Tumor Suppression

Equities Research | Equities.com |

Modulating expression of oncogenes and other disease-causing proteins (Image: Twentyeight-Seven Therapeutics)


Exonics Therapeutics Shows Restoral of Dystrophin Expression in Canine Model of Duchenne Muscular Dystrophy

Equities Research | Equities.com |

First study of Exonics’ gene editing technology in large mammals supports clinical advancement (Image: Exonics Therapeutics).


Emerging Growth

NXT-ID Inc.

Nxt-ID Inc provides products, solutions, and services that have a need for biometric secure access control. Its lines of business include mobile commerce; law enforcement and biometric access control applications…

Events

Guild's Quarterly Forecast

Join the whole Guild team on Wednesday, September 26 at 10 AM PDT for Guild’s Quarterly Forecast, our regular conference call and webinar on the most important trends affecting your…

Learn more